Chairs: Prof. Dr Raquel Duarte (Porto, Portugal), Prof. Dr Christoph Lange (Borstel, Germany)
Speaker: Dr Dominik Zenner (London, United Kingdom)

Discussants: Dr Gulnaz Isabekova-Landau (Bremen, Germany), Dr Rishab Rampradeep (Chennai, India)

Fees: Free for ERS members and non-members
Find out more about becoming a member

Please note: non-members will need to create a free myERS account to register for this activity.

Overview

Despite being a curable disease, tuberculosis (TB) remains a leading cause of death worldwide, largely driven by social and economic factors. A purely biomedical approach is insufficient to end the TB epidemic. There is a critical educational need to shift the perspective of healthcare professionals, researchers, and policymakers towards understanding and addressing the root causes of TB - namely poverty, poor housing, malnutrition, and healthcare inequity. This webinar will provide the crucial context needed to develop more effective, equitable, and holistic TB control strategies, aligning with the WHO's End TB Strategy and global health equity goals.

Topics:

• The direct links between poverty, inequality, and TB incidence.
• Housing, overcrowding, and their role in TB transmission.
• Nutrition, food insecurity, and vulnerability to active TB disease.
• Barriers to healthcare access throughout the TB care cascade (diagnosis, treatment, adherence).
• Multi-sectoral strategies and policies to address these social determinants.

Format

60 minute webinar with presentation and panel discussion including Q&A session.

Learning outcomes

Following this webinar, participants will be able to:

1. Describe the core Social Determinants of Health (SDOH) and their mechanistic links to the TB cascade from infection to outcome.
2. Analyse how conditions like overcrowded housing and malnutrition increase the risk of TB transmission and progression.
3. Identify systemic barriers that limit access to TB prevention, diagnosis, and care for vulnerable populations.
4. Evaluate potential cross-sectoral interventions and policies aimed at mitigating the impact of social determinants on TB.

CME credit

An application for accreditation of this webinar has been made to the European Board for Accreditation in Pneumology (EBAP) for 1 CME credit per 1-hour attendance. If accredited, the CME credit will be granted upon attendance of at least 60 minutes during the live webinar only.

What is a webinar?

A webinar closely simulates a lecture-based teaching experience. The speaker can interact with the audience, just as in a classroom setting. During the webinar, you will be asked to share your opinion on issues related to the topic using interactive polls.

All participants will be able to hear the lecturer and see the slides throughout the presentation. As a participant you will be able to pose questions or discuss ideas with the other participants via the text chat facility and the speaker will respond to the questions via the microphone.

Login guidelines

More information will be communicated in due course.

• Please log in to the webinar 20 minutes before it is scheduled to commence. If you have any technical difficulties whilst trying to log in or during the session please contact e-learning@ersnet.org.
• Check Central European Summer Time.
• To achieve the best quality, we recommend to avoid downloading anything from the internet during your connection to the lecture and stopping all other programmes.
• Please also ensure that your audio settings are not set to mute and adjust the volume to a comfortable level.

About UNITE4TB

UNITE4TB is a public-private partnership with representation from academic institutions, small- and medium-sized enterprises (SMEs), public organisations, and pharmaceutical companies. The 7-year, €185 million project aims to accelerate and improve the clinical evaluation of combinations of existing and novel drugs, with the goal of developing new and highly active tuberculosis (TB) treatment regimens for drug-resistant and drug-sensitive TB. For more information, visit the consortium website: www.unite4TB.org

Funding

The UNITE4TB project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101007873. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA, Deutsches Zentrum für Infektionsforschung e. V. (DZIF), and Ludwig-Maximilians-Universität München (LMU). EFPIA/AP contribute to 50% of funding, whereas the contribution of DZIF and the LMU University Hospital Munich has been granted by the German Federal Ministry of Education and Research. For further information: www.imi.europa.eu

Disclaimer

This communication reflects the author's view. Neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.